. Strength. All Nonmedicinal Ingredients. Oral. Tablet 60 mg and 90 mg Dibasic calcium phosphate, ferric oxide black. (60 mg coating), ferric
Official health care professional site for BRILINTA® (ticagrelor) tablets indicated to reduce the rate of CV death, MI, and stroke in patients with acute coronary syndrome (ACS). Find information about dosage, mechanism of action and more.
Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start taking this medicine You are allergic to ticagrelor or any of the other ingredients of this medicine (listed in . for as long as your doctor keeps prescribing it.
HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA. BRILINTA® (ticagrelor) tablets, for oral use. Initial U.S. Approval: 2011. WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE
BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on Brilinta, talking to your doctor, and understanding your heart attack.
26 May 2017 renal failure which is more common when Zurampic is given alone, as it should be used in combination with a xanthine oxidase inhibitor. • Brilinta has a warning in its prescribing information regarding discontinuation of the medicine. Missed doses of Brilinta increase the risk of heart attack and stroke.
Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated (see section 4.3). Only limited information is available in patients with moderate hepatic impairment. Dose adjustment is not recommended, but ticagrelor should be used with caution (see

Annons

The photo has no tags

February 2018